UK | pharmaphorum

UK

News

NICE changes its mind on Novartis’ progressive MS drug Mayze...

UK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down earlier this year in draft guidance.

News

UK pledges £571m to equitable COVID-19 vaccine access scheme

UK Prime Minister Boris Johnson has told the UN General Assembly that the UK will donate £571 million ($735 million) to the COVAX scheme aimed at distributing COVID-19 vaccines fairly aroun

News

UK extends COVID-19 vaccine supply deal with Valneva

The UK government has signed a €1.4 billion ($1.66 billion) order for up to 190 million doses of a coronavirus vaccine in development at French company Valneva.

Views & Analysis

Rises in non-submissions to NICE: do they matter?

Leela Barham asks why companies may choose to not submit their drugs to NICE and keep them off routine commissioning – a trend that appears to be on the rise.

Views & Analysis

NHS telemedicine ambitions approach a pivotal point

The UK government has said it is vital to adopt telemedicine across the NHS in response to COVID-19 – but is the health service ready to fully embrace this digital tech?

News

UK’s second go at a contact tracing app heads for pilot stud...

After ditching its home-grown attempt at a coronavirus contact-tracing app for smartphones, the UK is ready to start pilot trials of a second version based on a platform develo

NICE changes its mind on Novartis’ progressive MS drug Mayze...

UK pledges £571m to equitable COVID-19 vaccine access scheme

UK extends COVID-19 vaccine supply deal with Valneva

Rises in non-submissions to NICE: do they matter?

NHS telemedicine ambitions approach a pivotal point

UK’s second go at a contact tracing app heads for pilot stud...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

UK

Editor's Picks